Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Zhu Baoguo: Continuous Innovation, Keeping Pace with the Great Times
Published Time：
2018-12-18
Standing at a new era and embarking on a new journey. Zhu Baoguo, Chairman of Health Yuan Pharmaceutical Group, stated that 2018 will be a year for Health Yuan to continue increasing R&D investment and continuous innovation in the professional fields of biomedicine and precision medicine, giving full play to the company's scientific research and competitive advantages in monoclonal antibodies, microspheres, respiratory drugs, and other areas, and continuing to lead the upgrade of the greater health industry.
On this occasion of the Spring Festival, Zhu Baoguo extended New Year greetings to consumers worldwide through Xinhua Net: I would like to express special thanks to friends from all walks of life who have supported and followed Health Yuan's development over the years. In addition to extending New Year's blessings and sincere greetings, I also hope to work together with everyone, full of confidence and expectations, to welcome a new journey.
Zhu Baoguo believes that 2017 was a year in which the pharmaceutical industry ushered in development opportunities, with continued encouragement for pharmaceutical innovation; the implementation of multiple promotional policies; the in-depth promotion of consistency evaluation; the formal implementation of the "two-invoice system"; and the "19th National Congress" report clearly stated the "implementation of the Healthy China strategy" and "providing comprehensive and life-cycle health services to the people." Under the multiple transformations of the pharmaceutical industry environment, Health Yuan has written achievements and harvests with a steady pace of development.
According to the introduction, in terms of scientific research, research and development products such as ipratropium bromide aerosol and budesonide aerosol have successively entered the clinical stage; the approval and listing of injectable esomeprazole sodium under its subsidiary company, the clinical launch of Lupron microspheres, the dual reporting and approval of PD-1, and smooth progress; its R&D team has not only obtained national key scientific and technological projects sub-project approval and special funds with key technologies, but also won the National Science and Technology Progress Award. Under the national key support and efforts to promote the pharmaceutical industry, Health Yuan continues to cultivate its expertise in medical technology, continuously consolidating and increasing its scientific and technological innovation strength.
China's current development has entered a new stage, with the innovation-driven strategy running through the beginning and end of the development of various industries. Zhu Baoguo stated that the new year is an important period for the pharmaceutical industry to make great achievements. The general trend is such that if we do not advance, we will retreat. Health Yuan will, on the basis of group and scale development, fully activate the initiative and creativity of both the group and its subsidiaries, strengthen the industrial chain layout of precision medicine, achieve the extension from the research, development, and sales of precision diagnosis-related equipment and reagents to precision medicine-related testing service businesses, effectively strengthening the industrial chain advantages; and improve the "medical and health care map" with the help of mobile medical service platforms, continuing to focus on the "innovative mission" action, adhering to product research and development innovation drive, and promoting the group's innovative practices to a new level.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.